A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
Solid Tumors With FGFR2 Alterations, Adult
DRUG: 3HP-2827
Dose Escalation Stage- incidence of adverse events (AEs), From baseline up until 28 days after the final dose|Dose Escalation Stage- incidence of dose-limiting toxicities (DLTs), Days 1-28 of Cycle 1 (a cycle is 28 days)|Dose Escalation Stage -Percentage of Participants With Changes From Baseline in Targeted Vital Signs, From baseline up until 28 days after the final dose|Dose Escalation Stage -Percentage of Participants With Changes From Baseline in Targeted Clinical Laboratory Test Results, From baseline up until 28 days after the final dose|Dose Escalation Stage -Percentage of Participants With Changes From Baseline in Targeted ECG Parameters, From baseline up until 28 days after the final dose|Dose Escalation Stage -determine the maximum tolerated dose (MTD) and/or the recommended dose (RD) for expansion stage or recommended Phase II dose (RP2D) of 3HP-2827, Initiation of study drug until study discontinuation, (up to approximately 24 months)|Expansion stage -Objective response rate（ORR）, ORR refers to the percentage of patients with best overall response of confirmed CR or PR from the start of study treatment to patient withdrawal due to PD., Initiation of study drug until disease progression (up to approximately 36 months)
Maximum concentration (Cmax) during the dosing interval of 3HP-2827 and/or its major metabolites as monotherapy., Initiation of study drug until study discontinuation, (up to approximately 24 months))|Time to maximum concentration (Tmax) of 3HP-2827 and/or its major metabolites as monotherapy., Initiation of study drug until study discontinuation, (up to approximately 24 months))|Apparent clearance (CL/F) of 3HP-2827 and/or its major metabolites as monotherapy., Initiation of study drug until study discontinuation, (up to approximately 24 months))|Area under the concentration-time curve (AUC) of 3HP-2827 and/or its major metabolites as monotherapy., Initiation of study drug until study discontinuation, (up to approximately 24 months))|Terminal half life (t1/2) of 3HP-2827 and/or its major metabolites as monotherapy., Initiation of study drug until study discontinuation, (up to approximately 24 months))|Apparent volume of distribution (Vz/F) of 3HP-2827 and/or its major metabolites as monotherapy., Initiation of study drug until study discontinuation, (up to approximately 24 months))|Duration of Response (DOR) as assessed by RECIST v1.1, DOR refers to the time period from the first evaluation of confirmed CR or PR (whichever occurs first) to PD or death., Up to 45 months|Disease control rate (DCR) as assessed by RECIST v1.1, DCR refers to the percentage of patients with best overall response of confirmed CR, PR or SD from the start of study treatment to patient withdrawal due to PD., Up to 45 months|Progression-free survival (PFS) as assessed by RECIST v1.1, PFS refers to the time between the date of first dose and the first PD or death due to any cause based on the investigator's imaging review results, Up to 45 months|Overall survival (OS), OS refers to the time from the date of first dose to the date of death due to any cause., Up to 48 months|Dose escalation stage - Objective Response Rate (ORR), ORR refers to the percentage of patients with best overall response of confirmed CR or PR from the start of study treatment to patient withdrawal due to PD., Up to 45 months|Expansion Stage- incidence of adverse events (AEs), From baseline up until 28 days after the final dose|Expansion Stage -Percentage of Participants With Changes From Baseline in Targeted Vital Signs, From baseline up until 28 days after the final dose|Expansion Stage -Percentage of Participants With Changes From Baseline in Targeted Clinical Laboratory Test Results, From baseline up until 28 days after the final dose|Expansion Stage -Percentage of Participants With Changes From Baseline in Targeted ECG Parameters, From baseline up until 28 days after the final dose|Expansion Stage -Changes in patient-reported outcomes as assessed by the European Organization for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30) in patients with advanced solid tumors, From baseline up until 28 days after the final dose
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.